About Alaxia

Alaxia is a French private biotech company developing therapeutic solutions for respiratory diseases based on its proprietary peroxidase platform. The most advanced drug candidate, ALX-009, is an antimicrobial innovative compound aiming at treating cystic fibrosis, including the most resistant bacterial strains.

HISTORY

  • 2008

    Founded in 2008, Alaxia is a private biotech company based in Lyon (France)

  • 2011

    Incorporated in Stragen Group in 2011  

  • 2014

    BPIFRANCE INVESTS OVER 10 MILLION EUROS IN THE ALIPEX PROGRAM About Bpifrance’s Strategic Industrial Innovation programs: the SII program encourages the emergence of European champions. It supports ambitious, innovative and collaborative industrial projects for small and medium-sized companies (up to 5000 employees). These projects have a high potential in that they are focused on bringing breakthrough technologies to the marketplace, spurred on with the support of public funding.

  • 2016

    Cystic Fibrosis Foundation supports ALX-009 program